These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6858544)

  • 1. Hypoglycemic treatments and the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations.
    Gamba G; Grignani G; Biancardi M; De Marco R; Grassi M; Ferrari E
    Acta Diabetol Lat; 1983; 20(1):63-70. PubMed ID: 6858544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations.
    Gamba G; Grignani G; Montera V; Perotti G; Ragone L; Ascari E
    Ric Clin Lab; 1983; 13(3):337-45. PubMed ID: 6648238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of fibrinolytic activity in obese diabetics after treatment with Silubin retard.
    Mincu I; Dumitrescu C; Mihalache N
    Rev Roum Med Intern; 1973; 10(1):23-7. PubMed ID: 4694840
    [No Abstract]   [Full Text] [Related]  

  • 4. Antifibrin action of phenformin.
    Banerjee RN; Kumar V; Rao SR; Sahni AL; Arya M; Bardhan J
    Diabetologia; 1975 Apr; 11(2):105-11. PubMed ID: 1149944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycemic therapy and hemostasis in maturity- onset diabetes mellitus: existence of an early prethrombotic state.
    Grignani G; Gamba G; Biancardi M; De Marco R; Grassi M; Ferrari E
    Acta Diabetol Lat; 1982; 19(1):29-35. PubMed ID: 6803480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen content and fibrinolytic activity of blood in diabetics, before and after antidiabetic drugs.
    Bedi HK; Vyas BR; Bomb BS; Agarwal ML; Bedi T
    J Assoc Physicians India; 1977 Mar; 25(3):181-5. PubMed ID: 914747
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with glibenclamide in maturity-onset diabetes mellitus.
    Persson I; Madsen SN
    Geriatrics; 1971 May; 26(5):182-95. PubMed ID: 5004113
    [No Abstract]   [Full Text] [Related]  

  • 8. Chlorpropamide and fibrinolytic activity in maturity onset diabetes mellitus.
    Alexander WD; Wensley RT; Price G; Hartog M
    Postgrad Med J; 1976 May; 52(607):251-3. PubMed ID: 959097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective view of the treatment of adult-onset diabetes with special reference to the University Group Diabetes Program and oral hypoglycemic agents.
    Prout TE
    Med Clin North Am; 1971 Jul; 55(4):1065-75. PubMed ID: 4946757
    [No Abstract]   [Full Text] [Related]  

  • 10. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics.
    Nattrass M; Todd PG; Hinks L; Lloyd B; Alberti KG
    Diabetologia; 1977 Apr; 13(2):145-52. PubMed ID: 404205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic activity and diabetes control--evidence for a relationship. A preliminary report.
    Gunnarsson R; Nyman D; Wålinder O; Ostman J
    Acta Med Scand Suppl; 1980; 639():23-4. PubMed ID: 6932810
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoglycemic drugs.
    Stehling L
    Clin Anesth; 1974; 10(1):233-47. PubMed ID: 4598996
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral hypoglycemic agent update.
    Krall LP; Chabot VA
    Med Clin North Am; 1978 Jul; 62(4):681-94. PubMed ID: 98675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of hypoglycemic drugs on hemostasis].
    Spasov AA; Kucheriavenko AF; Salaznikova OA
    Eksp Klin Farmakol; 2010 Aug; 73(8):26-8. PubMed ID: 20919554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Considerations on diabetic angiopathies. Relations to hypoglycemic treatments].
    Lubetzki J
    Nouv Presse Med; 1972 Mar; 1(11):715-8. PubMed ID: 5022249
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.
    Melidonis A; Stefanidis A; Tournis S; Manoussakis S; Handanis S; Zairis M; Dadiotis L; Foussas S
    Clin Cardiol; 2000 Mar; 23(3):160-4. PubMed ID: 10761802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients.
    Gram J; Jespersen J
    Metabolism; 1992 May; 41(5 Suppl 1):25-9. PubMed ID: 1574011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin powder turbidity measurement for rapid assessment of antiplasmins.
    Exner T; Rickard KA; Kronenberg H
    Am J Clin Pathol; 1975 Nov; 64(5):597-601. PubMed ID: 127526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.